(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
In blow to Lula, Brazil Congress revives controversial environmental bill - 2Figure out How to Explore Land Close to 5G Pinnacles
- 34 Family SUVs: Joining Solace and Style
- 4Find the Advantages of Deep rooted Getting the hang of: Extending Information and Self-awareness
- 5The Best 10 Innovation Developments of the Year
- Instructions to Pick the Ideal SUV Size for Seniors
- Track down Your Optimal Conservative Vehicle: Famous Brands to Consider
- Bird flu poses risk of pandemic worse than COVID, France's Institut Pasteur says
- 'Israel has the right to continue its attacks,' Lebanese Foreign Minister announces
- In vogue Sleepwear Patterns for 2024
- Become the best at Discussion: 6 Procedures for Progress
- One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- Flourishing in Retirement: Individual Accounts of Post-Profession Satisfaction
